Upon the announcement of the 2025 Nobel Prize in Physiology or Medicine, Dr. Mary Brunkow’s name was prominent as a testament to her perseverance and quiet genius. She had won the highest honor in science for decades of studying the immune system, its balance, its errors, and its remarkable precision.
Brunkow, one of three laureates honored for exposing how the body’s immune defenses know when to fight and when to back off, works out of her research base at the Institute for Systems Biology in Seattle. She shed light on the complex dance of regulatory T-cells, the protectors of immune peace, alongside Fred Ramsdell and Shimon Sakaguchi. These cells stop the immune system from attacking its own body because they are directed by the FOXP3 gene.
Because it provided an incredibly clear explanation for one of medicine’s oldest mysteries—why some people develop autoimmune diseases while others are unaffected—her discovery was especially groundbreaking. Scientists suspected a genetic cause prior to Brunkow’s work, but they were unable to pinpoint the switch. Her discovery of FOXP3 permanently altered that.
Mary Brunkow — Personal and Professional Information
| Category | Details |
|---|---|
| Full Name | Dr. Mary E. Brunkow |
| Year of Birth | 1961 |
| Nationality | American |
| Education | Ph.D., Princeton University |
| Current Role | Senior Program Manager, Institute for Systems Biology, Seattle, USA |
| Field | Immunology, Molecular Biology |
| Nobel Prize | Nobel Prize in Physiology or Medicine (2025) |
| Co-Laureates | Fred Ramsdell (Sonoma Biotherapeutics), Shimon Sakaguchi (Osaka University) |
| Major Discovery | Identification of the FOXP3 gene linked to immune regulation and autoimmune disease |
| Reference | NobelPrize.org |
Brunkow and Ramsdell identified the cause of severe autoimmune reactions in a strain of lab mice through systematic experimentation. Their discovery of a single genetic defect—a mutation that essentially rendered immune restraint inoperable—was the turning point. In addition to opening the door for treatments that could revolutionize the way that lupus, type 1 diabetes, and multiple sclerosis are treated, the discovery was remarkably successful in linking a molecular defect to immune dysfunction.
Brunkow’s Nobel-winning research has a lesson about balance at its core. As she frequently explained, the immune system is a dialogue—a dynamic balancing act between attack and tolerance—rather than merely a battlefield. By proving that immune harmony is just as important as immune defense, her work reinterpreted that relationship.
Her co-laureate, Shimon Sakaguchi, who discovered regulatory T-cells for the first time in 1995, put decades of effort into this accomplishment. Brunkow’s contribution was to demonstrate the development of these cells and the reasons behind their occasional failure. Her discoveries connected the molecular to the clinical, bridging biology, medicine, and genetics with a grace that scientists found especially novel.
Brunkow’s tale also exemplifies the quiet fortitude of female scientists. In an area where gender representation is still a problem, her acknowledgment feels extremely symbolic. Similar to Jennifer Doudna’s 2020 Nobel Prize for CRISPR technology, Brunkow’s victory emphasizes that teamwork, not rivalry, is frequently the means of discovery. Her lab has become a model for an inclusive research culture because of her leadership style, which colleagues have characterized as “a leader who listens more than she speaks.”
Brunkow’s curiosity-driven approach was already well-known at Princeton, where she received her Ph.D. She was remembered by professors as a person who possessed both a genuine empathy for the human side of science and extremely efficient reasoning. She frequently referred to biology as “a story about connection,” a viewpoint that persisted in her research on immune tolerance. Her findings are not merely theoretical; they are profoundly human, which may be the reason why doctors who treat autoimmune diseases find her research so compelling.
Her team’s demonstration of how the immune system’s restraint mechanisms stop the body from attacking itself was commended by the Nobel Committee. According to committee chair Olle Kämpe, “their discoveries have been decisive for understanding why we do not all develop autoimmune diseases.” These discoveries are especially helpful because they pave the way for treatments that offer a more sustainable and natural method of treatment by restoring immune balance rather than completely suppressing it.
A new generation of treatments is already being developed in clinical settings thanks to Brunkow’s discoveries. Her knowledge is being used by pharmaceutical researchers to create medications that can mimic or increase the activity of regulatory T-cells, potentially providing cures rather than chronic care. By lowering rejection rates without the severe side effects of immunosuppressants, such treatments may also greatly increase the safety of organ transplants.
Her Nobel honor has brought immunology back into the spotlight as a medical frontier, mirroring the excitement that swept the world after Katalin Karikó and Drew Weissman’s 2023 mRNA vaccine research. These significant events demonstrate how science driven by curiosity can change public health and the boundaries of patient care.
But the 64-year-old scientist is still humble about her influence. Brunkow recently called her accomplishment “a moment that belongs to everyone who has ever asked why” in an interview with the Seattle Post-Intelligencer. She acknowledged her fellow Nobel laureates and the ISB teams, emphasizing the spirit of collaboration that went into the award. Her story is remarkably similar to that of quiet innovators whose influence gradually increases due to her humility, humor, and meticulous intellect.
Her peers frequently remark that she embodies the ideal scientist: incredibly trustworthy, intensely inquisitive, and prepared to investigate issues that others might miss. In contrast to the fast-paced, headline-driven nature of contemporary research, her methodical approach serves as a reminder to many that real breakthroughs frequently develop gradually, much like the immune system itself—methodical, adaptive, and balanced.
